ArticleOncotarget2016

A novel compound which sensitizes BRAF wild-type melanoma cells to vemurafenib in a TRIM16-dependent manner.

Selina K Sutton et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.